Eli Lilly's Q2 Earnings Surge on High Demand for Weight-Loss Drugs

Mounjaro and Zepbound drive significant revenue growth, prompting increased full-year financial forecasts.

Eli Lilly's Q2 revenue hit $11.3 billion, exceeding Wall Street's $9.98 billion estimate.
Sales of Mounjaro and Zepbound totaled $4.3 billion, surpassing expectations by $1.1 billion.
The company's stock rose by 14% following the earnings announcement.
Full-year revenue guidance was raised to $45.4-$46.6 billion, up from $42.4-$43.6 billion.
Eli Lilly is addressing supply issues and planning to introduce a pill-based GLP-1 drug.